Standard of care for pregnant women with an opioid use disorder

Video length: 1:53


[Tile text, Standard of Care for Pregnant Women with an Opioid Use Disorder​]

Dr. Jones speaking: So, since the Mother Study was published in 2010, there have been a number of guidelines that have come out both internationally as well as within the United States. For example, the W-H-O, the World Health Organization guidelines were published in 2014 and those guidelines clearly state that for women who have an opioid use disorder while they’re pregnant, there are two medications that are a standard of care to treat them, methadone or buprenorphine. For the United Nations there are international standards of drug treatment and in those standards in the section about women and children it specifically stated that both methadone and buprenorphine are the accepted standard of care to treat opioid use disorder during pregnancy. As well, the American Society of Addiction Medicine and the ACOG Organization have also endorsed methadone and buprenorphine acceptable practices to treat opioid use disorder during pregnancy.

[Tile text, Despite the Evolving Guidelines, Obstacles Remain]

So, some of the obstacles to women to be able to receive a medication assisted treatment like methadone and buprenorphine during pregnancy include just sheer non-availability of those medications in their local communities. Sometimes methadone clinics are hundreds of miles away from where women live, or sometimes there are not enough buprenorphine waiver providers that are able to prescribe the medication to women, so access is definitely a huge driving barrier for women to receive medication assisted treatment during pregnancy.

[End slate with HHS and NIDA logo and website,]